191 related articles for article (PubMed ID: 34959980)
41. FDA Supplemental Approval Summary: Lenvatinib for the Treatment of Unresectable Hepatocellular Carcinoma.
Nair A; Reece K; Donoghue MB; Yuan WV; Rodriguez L; Keegan P; Pazdur R
Oncologist; 2021 Mar; 26(3):e484-e491. PubMed ID: 33044793
[TBL] [Abstract][Full Text] [Related]
42. Poor tolerability of lenvatinib in elderly patients ≥80 years old with hepatocellular carcinoma: A multicenter observational study.
Kinoshita A; Hagiwara N; Osawa A; Akasu T; Matsumoto Y; Ueda K; Saeki C; Oikawa T; Koike K; Saruta M
J Oncol Pharm Pract; 2023 Apr; 29(3):626-636. PubMed ID: 35112972
[TBL] [Abstract][Full Text] [Related]
43. L-Carnitine Suppresses Loss of Skeletal Muscle Mass in Patients With Liver Cirrhosis.
Ohara M; Ogawa K; Suda G; Kimura M; Maehara O; Shimazaki T; Suzuki K; Nakamura A; Umemura M; Izumi T; Kawagishi N; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ohnishi S; Sakamoto N
Hepatol Commun; 2018 Aug; 2(8):906-918. PubMed ID: 30094402
[TBL] [Abstract][Full Text] [Related]
44. Extracellular water to total body water ratio obtained by bioelectrical impedance analysis determines the dose intensity of lenvatinib for the treatment of patients with advanced hepatocellular carcinoma.
Yamaoka K; Kodama K; Hiramatsu A; Ando Y; Kosaka Y; Suehiro Y; Fujii Y; Uchikawa S; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Kawaoka T; Miki D; Tsuge M; Imamura M; Takahashi S; Chayama K; Aikata H
J Gastroenterol Hepatol; 2021 Jun; 36(6):1685-1693. PubMed ID: 33326154
[TBL] [Abstract][Full Text] [Related]
45. Risk Factors of Proteinuria in Patients with Hepatocellular Carcinoma Receiving Lenvatinib.
Ikesue H; Yamamoto H; Hirabatake M; Hashida T; Chung H; Inokuma T; Muroi N
Biol Pharm Bull; 2022; 45(3):333-338. PubMed ID: 35228399
[TBL] [Abstract][Full Text] [Related]
46. [A Case of Advanced Hepatocellular Carcinoma That Caused Rapid Re-Growth Due to Lenvatinib Withdrawal].
Oyama K; Maeda S; Nakahira S; Kitagawa A; Ushimaru Y; Ohara N; Miyake Y; Makari Y; Nakata K; Fujita J
Gan To Kagaku Ryoho; 2021 Dec; 48(13):1586-1588. PubMed ID: 35046264
[TBL] [Abstract][Full Text] [Related]
47. Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study.
Fu Z; Li X; Zhong J; Chen X; Cao K; Ding N; Liu L; Zhang X; Zhai J; Qu Z
Hepatol Int; 2021 Jun; 15(3):663-675. PubMed ID: 33877527
[TBL] [Abstract][Full Text] [Related]
48. Exploratory analysis of target concentration of lenvatinib in the treatment of hepatocellular carcinoma.
Noda S; Iida H; Fujimoto T; Wakasugi Y; Yabuta N; Sudou M; Hira D; Tani M; Andoh A; Morita SY; Terada T
Cancer Chemother Pharmacol; 2021 Aug; 88(2):281-288. PubMed ID: 33928425
[TBL] [Abstract][Full Text] [Related]
49. Two Cases of Intraabdominal Bleeding Caused by Hepatocellular Carcinoma Rupture Soon after the Initiation of Chemotherapy with Lenvatinib.
Sato A; Imai Y; Uchiya H; Uchida Y; Nakazawa M; Sugawara K; Nakayama N; Mochida S
Intern Med; 2022 Aug; 61(15):2301-2305. PubMed ID: 35283380
[TBL] [Abstract][Full Text] [Related]
50. A change in the timing for starting systemic therapies for hepatocellular carcinoma: the comparison of sorafenib and lenvatinib as the first-line treatment.
Hatanaka T; Kakizaki S; Nagashima T; Ueno T; Namikawa M; Tojima H; Takizawa D; Naganuma A; Arai H; Sato K; Harimoto N; Shirabe K; Uraoka T
Acta Gastroenterol Belg; 2021; 84(1):65-72. PubMed ID: 33639695
[TBL] [Abstract][Full Text] [Related]
51. Percutaneous transvenous shunt occlusion for portosystemic encephalopathy due to lenvatinib administration to a patient with hepatocellular carcinoma and portosystemic shunt.
Namba M; Kawaoka T; Aikata H; Kodama K; Uchikawa S; Ohya K; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Tsuge M; Hiramatsu A; Imamura M; Baba Y; Awai K; Chayama K
Clin J Gastroenterol; 2019 Aug; 12(4):341-346. PubMed ID: 30706429
[TBL] [Abstract][Full Text] [Related]
52. Real-world effectiveness of lenvatinib monotherapy among unresectable hepatocellular carcinoma patients in the USA.
Singal AG; Nagar SP; Hitchens A; Davis KL; Iyer S
Future Oncol; 2021 Jul; 17(21):2759-2768. PubMed ID: 33832339
[TBL] [Abstract][Full Text] [Related]
53. Optimal management of patients with hepatocellular carcinoma treated with lenvatinib.
Ikeda M; Kobayashi M; Tahara M; Kaneko S
Expert Opin Drug Saf; 2018 Nov; 17(11):1095-1105. PubMed ID: 30264594
[TBL] [Abstract][Full Text] [Related]
54. Analysis of Post-Progression Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib.
Ando Y; Kawaoka T; Suehiro Y; Yamaoka K; Kosaka Y; Uchikawa S; Kodama K; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Tsuge M; Hiramatsu A; Fukuhara T; Mori N; Takaki S; Tsuji K; Nonaka M; Hyogo H; Aisaka Y; Masaki K; Honda Y; Moriya T; Naeshiro N; Azakami T; Takahashi S; Imamura M; Chayama K; Aikata H
Oncology; 2020; 98(11):787-797. PubMed ID: 32882687
[TBL] [Abstract][Full Text] [Related]
55. Association between Skeletal Muscle Depletion and Sorafenib Treatment in Male Patients with Hepatocellular Carcinoma: A Retrospective Cohort Study.
Naganuma A; Hoshino T; Suzuki Y; Uehara D; Kudo T; Ishihara H; Sato K; Kakizaki S; Yamada M; Takagi H
Acta Med Okayama; 2017 Aug; 71(4):291-299. PubMed ID: 28824184
[TBL] [Abstract][Full Text] [Related]
56. Can levocarnitine supplementation improve fatigue caused by sunitinib as a treatment for renal cell carcinoma? A single-center prospective pilot study.
Shindo T; Kobayashi K; Tanaka T; Masumori N
Support Care Cancer; 2019 Apr; 27(4):1491-1496. PubMed ID: 30374764
[TBL] [Abstract][Full Text] [Related]
57. Potential and Clinical Significance of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Evaluating Liver Cancer Response to Lenvatinib Treatment.
Yamashige D; Kawamura Y; Kobayashi M; Shindoh J; Kobayashi Y; Okubo S; Muraishi N; Kajiwara A; Iritani S; Fujiyama S; Hosaka T; Saitoh S; Sezaki H; Akuta N; Suzuki F; Suzuki Y; Ikeda K; Arase Y; Hashimoto M; Kumada H
Oncology; 2021; 99(3):169-176. PubMed ID: 33207358
[TBL] [Abstract][Full Text] [Related]
58. Impact of Early Lenvatinib Administration on Survival in Patients with Intermediate-Stage Hepatocellular Carcinoma: A Multicenter, Inverse Probability Weighting Analysis.
Tada T; Kumada T; Hiraoka A; Michitaka K; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Yasuda S; Toyoda H; Fukunishi S; Ohama H; Kawata K; Nakamura S; Nouso K; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Joko K; Koizumi Y; Hiasa Y;
Oncology; 2021; 99(8):518-527. PubMed ID: 33906189
[TBL] [Abstract][Full Text] [Related]
59. Impact of branched-chain amino acids and frailty on the management of lenvatinib-related fatigue in patients with hepatocellular carcinoma.
Shimose S; Koya S; Kawaguchi T; Hirota K; Yoshio S; Niizeki T; Matsuse H; Torimura T
Clin Mol Hepatol; 2021 Oct; 27(4):616-619. PubMed ID: 34517441
[No Abstract] [Full Text] [Related]
60. Lenvatinib as a therapy for unresectable hepatocellular carcinoma.
Spallanzani A; Orsi G; Andrikou K; Gelsomino F; Rimini M; Riggi L; Cascinu S
Expert Rev Anticancer Ther; 2018 Nov; 18(11):1069-1076. PubMed ID: 30220234
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]